By Sudeshna Ray
Edited by Neha Mehrotra
Lede illustration by Kavipriya OG

Introduction: Breaking the Private Equity Mold

For the better part of the last decade, India’s healthcare sector has been locked in a familiar financial choreography. Private equity heavyweights—such as Temasek, Blackstone, TPG, and KKR—have flooded the market with capital, injecting over $15.5 billion into domestic healthcare enterprises over the past five years alone. Within this deluge of institutional capital, hospitals and specialized care clinics have captured the lion’s share, absorbing roughly 60% of all deployed funds.

For most growing medical chains, tapping a healthcare-focused private equity fund is treated as an industry rite of passage. It provides the heavy financial artillery needed to fund rapid, aggressive expansion, typically through a localized acquisition spree.

Yet, exactly one year ago, Coimbatore-headquartered eye-care chain The Eye Foundation decided to rewrite this script. Celebrating its 40th anniversary and embarking on its first-ever external equity round, the seasoned eye-care provider completely bypassed traditional healthcare-focused institutional funds. Instead, it pursued a surprisingly unconventional suitor: Verlinvest, a consumer-brands and retail venture capital fund historically known for backing lifestyle and fast-moving consumer goods (FMCG) darlings like yogurt brand Epigamia, sleep-solutions provider Wakefit, and beauty-and-personal-care platform Purplle.

In October 2025, the crossover partnership materialized into a landmark Rs 650 crore transaction, securing Verlinvest a 20% stake in the regional powerhouse.

The move has sent ripples across India’s booming specialized healthcare sector, highlighting a strategic divide between traditional, growth-at-all-costs acquisition models and patient, brand-centric capital deployment.

Chronology of a Milestone Deal: How The Eye Foundation Chose Its Partner

To understand how a traditional eye-care enterprise landed in the portfolio of an FMCG-focused venture capital firm, one must look at the timeline of the company’s maturation and financial trajectory.

The Foundation and Steady Growth

Founded four decades ago in Coimbatore, Tamil Nadu, under the visionary leadership of founder and CEO Dr. D. Ramamurthy, The Eye Foundation built its reputation on clinical excellence and steady, organic expansion. Unlike many of its venture-backed peers that prioritized breakneck geographic expansion over foundational stability, the chain maintained a remarkably robust balance sheet.

By the time the company actively pursued external capital, its financial health had turned heads across the financial ecosystem. The Eye Foundation’s revenue metrics demonstrated consistent, compound growth:

• FY24: Rs 278 crore
• FY25: Rs 330 crore
• FY26: Rs 409 crore
• FY27 (Projected): Rs 550 crore (on track to achieve an explosive ~90% year-on-year jump)

The Influx of "Suitors"

Because of its strong financials and clean balance sheet, the company found itself fielding interest from multiple institutional investors. Founder D. Ramamurthy noted that the chain had quite a few "suitors" knocking at its door.

However, the leadership team quickly realized that standard healthcare private equity funds came with strings attached—most notably, exit timelines and an aggressive pressure to consolidate through rapid acquisitions. Rather than succumbing to industry norms, The Eye Foundation evaluated prospective partners based on valuation, philosophical alignment, and long-term vision. Ultimately, Verlinvest emerged as the frontrunner, offering a valuation that rivaled competitor ASG Eye Hospital and comfortably surpassed the implied valuations of Dr. Agarwal’s latest institutional fundraises.

Supporting Data: Financial Health vs. Acquisition Burn

The divergence between The Eye Foundation’s strategy and that of its PE-backed competitors is stark when examining financial margins and capital allocation strategies.

Margin Defiance in a Regulated Sector

According to healthcare analysts, achieving and sustaining an EBITDA margin above 30% is a rare feat in India’s healthcare landscape—particularly given the heavy regulatory scrutiny, rising operational overheads, and pricing pressures facing the sector. Yet, The Eye Foundation has consistently hovered around an impressive 35% EBITDA margin.

To contextualize this performance against industry peers:

• The Eye Foundation: ~35% EBITDA margin (projected revenue of Rs 550 crore in FY27)
• Dr. Agarwal’s Eye Hospital: ~29% EBITDA margin (FY26)
• ASG Eye Hospital: ~22.6% EBITDA margin (FY25)

The PE Playbook: Acquisitions vs. Free Cash Flow

The operational differences run deeper than margins alone. Major eye-care chains backed by traditional private equity are currently wrestling with the aggressive growth mandates of their financial backers.

Consider the trajectory of Dr. Agarwal’s Eye Hospital, which is backed by private equity titans TPG and Temasek. The institutional duo injected a combined Rs 1,050 crore in 2022, followed by another Rs 640 crore in 2023. The vast majority of this capital was channeled directly into an aggressive acquisition spree to scale geographical footprints rapidly.

Data reveals the sheer scale of this cash burn: over the three-year period leading up to FY26, Dr. Agarwal’s deployed an astonishing Rs 1,215 crore on acquisitions. This heavy capital expenditure outpaced its internal generation capabilities, as the company generated only about Rs 315 crore in free cash flow during the exact same timeframe. While this strategy successfully expands national footprints, it places immense operational pressure on management to continually digest newly acquired clinics while maintaining service quality.

Official Responses and Perspectives: The Philosophy of "Patient Capital"

The decision to partner with a consumer-focused fund was not made lightly. In candid remarks, Dr. D. Ramamurthy addressed the unorthodox nature of the alliance, providing deep insight into the executive mindset.

"Choosing an FMCG fund is definitely unusual for the healthcare sector," acknowledged Dr. D. Ramamurthy, Founder and CEO of The Eye Foundation. "But we did not want a fly-by-night operator—somebody with a definite timeline who wants to exit in five years."

Traditional private equity funds typically operate on a strict 5-to-7-year fund lifecycle. Once this window closes, fund managers are contractually obligated to seek an exit, either through a secondary buyout, a trade sale, or an Initial Public Offering (IPO). This institutional constraint can force portfolio companies to prioritize short-term valuation spikes and aggressive top-line growth over sustainable, long-term clinical infrastructure.

By selecting Verlinvest—a family-backed investment firm known for holding assets over extended horizons and building enduring consumer brands—The Eye Foundation insulated itself from the ticking clock of traditional private equity.

Healthcare analysts consulted for this report noted that Verlinvest’s consumer-centric ethos might actually serve the eye-care chain well. Modern healthcare delivery, particularly in elective and specialized segments like ophthalmology, is increasingly mirroring retail consumer experiences. Patients act more like discerning consumers, demanding high-touch service, brand trust, seamless digital interfaces, and consistent quality across branches. Verlinvest’s deep expertise in scaling consumer-facing brand loyalty provides The Eye Foundation with strategic guidance that traditional hospital-focused PE funds rarely emphasize.

Broader Implications: Redefining Healthcare Investment in India

The Rs 650 crore deal between The Eye Foundation and Verlinvest signals a potential inflection point for how specialized medical chains approach financing, scaling, and brand building in India.

1. The Blurring Lines Between Healthcare and Consumer Retail

As disposable incomes rise and urban populations become more health-conscious, specialized medical services—such as eye care, dental clinics, dermatology, and IVF centers—are increasingly evaluated through a consumer lens. Patients are no longer just choosing a doctor based solely on local referrals; they are choosing branded healthcare chains that offer predictable, retail-like service experiences. Verlinvest’s investment validates this thesis, proving that consumer-focused venture capital can successfully crossover into clinical healthcare if the fundamentals are strong.

2. Pushing Back Against the Acquisition Treadmill

The heavy reliance on inorganic growth through acquisitions has defined Indian healthcare consolidation for the past decade. While chains like Dr. Agarwal’s and ASG have successfully scaled national footprints through this method, it requires constant capital injections and carries the risk of margin dilution and integration friction. The Eye Foundation’s ability to project a massive 90% revenue jump to Rs 550 crore in FY27 while maintaining a robust 35% EBITDA margin demonstrates that disciplined, brand-led, and selective expansion can rival the velocity of debt- or PE-fueled acquisition sprees.

3. A Shift in Founder Preferences

As more regional healthcare providers mature, founders are becoming increasingly protective of their corporate culture and clinical independence. The fear of being rushed into an early exit or forced into aggressive financial restructuring by short-term PE horizons is making alternative capital sources more attractive. The Eye Foundation’s playbook may well inspire other mid-sized, highly profitable healthcare chains to look beyond traditional healthcare funds and court investors who champion long-term enterprise building over rapid financial churn.

Conclusion: The Road Ahead

As The Eye Foundation enters its second year operating under the Verlinvest partnership, all eyes will be on its execution. With financial projections pointing toward Rs 550 crore in revenue by FY27 and profitability metrics that continue to defy industry norms, the Coimbatore-born chain has proven that stepping off the beaten path can yield extraordinary rewards.

In an industry dominated by private equity giants chasing rapid consolidation, The Eye Foundation’s bet on consumer-grade brand building and patient capital stands as a compelling testament to a different corporate philosophy—proving that sometimes, the best way to scale a hospital chain is to think like a consumer brand.